Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Biotech in post-TRIPS India

Nature Biotechnology volume 23, pages 18–19 (2005)Cite this article

To the editor:

The Indian government's substantial investment in patent infrastructure, together with recent modifications to Indian patent laws, reflects the country's commitment, both in letter and spirit, to adhering to the principles laid down by the World Trade Organization's (WTO, Geneva) agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). For India's biotech sector, however, a stronger patent system is unlikely to be sufficient to spark a boom of innovation. Indian companies simply cannot compete with the financial resources at the disposal of their Western counterparts. TRIPS implementation essentially signals the initiation of a race that is unfair.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ames, G. & Sunil, P. Indian pharmaceutical industry: market, regulatory, import and investment regime (Pacific Bridge, Inc., Washington, DC, 2002). http://www.pacificbridgemedical.com/publications/Indian_Pharma_Industry_2002.pdf

    Google Scholar 

  2. Ramani, S.V. & Maria A. TRIPS and its possible impact on the biotech based segment of the Indian pharmaceutical industry. Economic and Political Weekly, in the press (January 2005).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Economics, Institut National de la Recherche Agronomique; UMR INRA-UPMF, BP 47,

    Shyama V. Ramani & Mahesh Ravi

  2. UMR INRA-UPMF, BP 47, Grenoble, 38040, Cedex 9, France

    Shyama V. Ramani & Mahesh Ravi

  3. Department of Economics, University of California, 543 Evans Hall, c/o Jaeger, Berkeley, 94720, CA, USA

    Preeti Pradhan

Authors
  1. Shyama V. Ramani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Preeti Pradhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mahesh Ravi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shyama V. Ramani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramani, S., Pradhan, P. & Ravi, M. Biotech in post-TRIPS India. Nat Biotechnol 23, 18–19 (2005). https://doi.org/10.1038/nbt0105-18b

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0105-18b

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing